Answers are grounded in this paper and cite their sources.
This review outlines the appropriate noninvasive diagnostic workup for patients with suspected pulmonary hypertension, emphasizing the roles of echocardiography, V/Q scanning, and serologic testing to guide further invasive evaluation.
Diagnosing pulmonary arterial hypertension (PAH) requires a high index of clinical suspicion from even the most astute clinician, especially given the lack of specificity of the symptoms offered by the PAH patient. In addition, even mild elevations in pulmonary arterial pressure may represent fairly advanced pulmonary vascular disease making early detection difficult.1 As discussed by Dr Bull in the accompanying article, many clues from the history and physical may prompt further testing. In this segment, the noninvasive methods available to pursue a diagnosis of PAH will be reviewed.While electrocardiography lacks sufficient sensitivity to serve as an effective screening tool for PAH, it can contribute important prognostic information and should be performed. 1 Right ventricular hypertrophy and right-axis deviation can be detected 87% and 79% of the time in PAH.2 Findings suggestive of PAH include a tall R wave and small S wave (R/S ratio greater than 1) in lead V1, a large S wave and small R wave (R/S ratio less than 1) in lead V5 or V6, a qR complex in V1, an rSR' pattern in lead V1, or an S1S2S3 pattern. Right atrial enlargement should also be looked for, defined as a tall P wave in lead II, III, and aVF (greater than 2.5 mm) and a frontal P axis of 75 or greater. However, the absence of these findings does not exclude a diagnosis of PAH, with one study of 61 patients with PAH showing 8 with normal electrocardiograms despite severe PAH, and sensitivities of 73% for right-axis deviation and 55% for right ventricular hypertrophy noted.3 Specificity was only 70% in that population as well.3 The ECG may be helpful prognostically, independent of its role in diagnosis, in patients with established PAH since the presence of right atrial enlargement (P wave 0.25 millivolts or greater) has been associated with a 2.8-fold greater risk of death over a 6-year period of observation.4 The presence of electrocardiographic findings of right atrial enlargement, right ventricular hypertrophy, and right-axis deviation should prompt further evaluation in the patient with suspected PAH.Like the electrocardiogram, a chest radiograph should be obtained in all patients with suspected PAH even though it lacks sensitivity and specificity to establish a diagnosis. Suggestive clues that should be sought include attenuated peripheral markings, enlarged main and hilar pulmonary artery shadows, and obscuration of the retrosternal clear space on a lateral view due to an enlarged right ventricle. Lupi et al described a radiologic index in PAH defined as the ratio of the summed horizontal measurement of the pulmonary arteries from the midline to their first division divided by the entire transverse chest diameter.5 The chest radiograph may also define concomitant pulmonary parenchymal disease, pulmonary venous congestion (seen in pulmonary veno-occlusive disease), hyperinflation changes of chronic obstructive pulmonary disease (COPD), kyphosis, or findings suggestive of chronic thromboembolic pulmonary hypertension (CTEPH) such as mosaic oligemia, right ventricular hypertrophy, or an enlarged descending right pulmonary artery.6 The extent of radiographic abnormalities and the degree of PAH in any given patient do not appear to be correlated.1The reliability of Doppler echocardiography to quantify PAH has been extensively studied. While numerous studies report excellent correlation coefficients as a measure of accuracy, technical aspects of interrogation make tricuspid regurgitant jets (a requisite feature of systolic pulmonary arterial pressure estimates by the modified Bernoulli equation) analyzable in anywhere from 39%7 to 86%8 of patients. Patients with advanced lung disease may represent a challenge as estimates of systolic pulmonary arterial pressure were achievable in only 44% of 166 such patients in one study.9 When tricuspid and pulmonic valve regurgitant jets are not present or quantifiable, estimates of pulmonary diastolic pressures may be useful10 and these correlate well with right-heart catheterization measures.11 While correlations are generally strong with catheterization data the magnitude of difference between estimated and true pulmonary arterial pressure as measured by right-heart catheterization can be significant, with mean differences ranging from 3 to 38 mm Hg.1 Discordance is generally greatest at extremes, with underestimation common when systolic pulmonary arterial pressure is greater than 100 mm Hg.12 Advanced lung disease patients pose a special challenge, with 48% of patients misclassified as having PAH and 52% of pressure estimates inaccurate in a cohort of 374 patients being assessed for lung transplantation.9 Despite these caveats, the sensitivity and specificity of Doppler echocardiography range from 0.79 to 1.0 and 0.6 to 0.98, respectively.13–16The role of exercise echocardiographic testing to unmask PAH remains controversial. One study examined the features of the resting echocardiogram (with normal resting systolic pulmonary arterial pressure) in those with exercise-induced PAH and found that tricuspid regurgitation and right ventricular outflow velocity time integral at peak velocity distinguished exercise PAH from normal PAH.16 Interestingly, recent studies of idiopathic pulmonary hypertension (IPAH) family members suggest that supine bicycle exercise echocardiography may identify a subgroup of asymptomatic carriers of the PAH gene.1718Since false-positive testing is more common when the prevalence of disease is low, focused ordering of Doppler echocardiography in an asymptomatic population at risk is advisable,1 as overestimation of systolic pulmonary arterial pressure is more likely in populations with normal pressures. 1519 Risk factors that warrant screening echocardiography include known genetic mutations associated with PAH, a first degree relative with familial PAH (FPAH), a diagnosis of scleroderma, portal hypertension prior to liver transplantation, or congenital heart disease with systemic-to-pulmonary shunts.1 When PAH is suspected or estimated by Doppler echocardiography, a contrast “bubble” echocardiogram should be obtained to assess for left-to-right shunting.1 In addition, left atrial enlargement, even in the absence of left ventricular dysfunction, should raise the possibility of elevated left-sided pressures that may be contributing to the pulmonary pressure elevation seen. When present, right-heart catheterization, and often left-heart catheterization, to measure transpulmonary gradient and to assess for diastolic dysfunction is crucial.1In order to define PAH association with certain connective tissue disease, a serologic assessment should be performed in conjunction with features of the individual patient's history and exam findings. Since the most common connective tissue disease associated with PAH, limited scleroderma, typically will not manifest interstitial disease on exam or chest radiography, patients with perceived IPAH should be carefully assessed for features of systemic sclerosis. Estimates of PAH prevalence in scleroderma range from 4.9%20 to 38%.21 When PAH is present in association with diffuse scleroderma, U3-RNP antibodies are often positive. 22 When PAH develops in those with limited scleroderma it usually does so slowly1 and in association with 1) positive anticentromere antibodies,23 2) positive antinuclear antibodies including U3-RNP, B23, Th/To, and U1-RNP,24–26 and 3) marked reductions in diffusing capacity for carbon monoxide (DLCO) on pulmonary function testing.1327 In fact, 20% of those with limited scleroderma and isolated carbon monoxide diffusing capacity reductions of less than 55% of predicted values will acquire PAH within 5 years.28Other connective tissue diseases such as systemic lupus erythematosis, polymyositis, and rheumatoid arthritis are less commonly associated with PAH.2930 In mixed connective tissue disease, however, one study found that PAH was the most common cause of death, occurring in 38% of these patients.31 Anticardiolipin antibodies have been associated with PAH in at least two studies of systemic lupus erythematosis patients.3233 Human immunodeficiency virus (HIV) is associated with PAH in up to 0.5% of HIV infections,34 and HIV testing is advised in all appropriate cases of unexplained PAH.1 Evaluation for liver disease is also appropriate as 2% of these patients have been found to have PAH in one study.35 Thyroid function abnormalities have also been suggested as a risk factor for PAH, although it is unclear at present whether thyroid disease is causally related to PAH.1Since PAH develops as a complication of chronic thromboembolic disease (CTEPH) and can mimic IPAH, this potentially surgically remediable entity should be looked for in all patients with PAH.1 Indeed, one recent study concluded that CTEPH occurs in up to 4% of patients surviving their pulmonary embolism, usually within 2 years of the event.36 Ventilation-perfusion (V/Q) scanning is the screening method of choice, typically showing one or more segmental-sized mismatched defects.37 A normal V/Q scan effectively rules out CTEPH.3839 Perfusion scans alone tend to underestimate the severity of vessel obstruction in CTEPH.40 While both contrast-enhanced computerized tomography and magnetic resonance imaging have utility in defining alternative diagnoses (eg, sarcoma, vasculitis, mediastinal fibrosis) and may be complementary to V/Q scanning, these techniques should not be used to exclude the diagnosis of CTEPH.1 Pulmonary angiography is ultimately required for accurate diagnosis and anatomic definition of CTEPH and remains the procedure of choice.1Pulmonary function testing is an important adjunct in the initial evaluation of all patients with PAH. Restrictive defects are not uncommon in IPAH and CTEPH patients, with 20% demonstrating such defects at initial evaluation, 237 and mild diffusing capacity for carbon monoxide impairment is likewise often observed in these patients.41 Isolated abnormalities in carbon monoxide diffusing capacity occur in limited scleroderma1327 and, in fact, when severe (less than 55% of predicted), 35% of these patients will acquire demonstrable PAH within 5 years.28 A fall in the carbon monoxide diffusing capacity values is suggestive of early development of PAH.28 A widened alveolar-arterial oxygen gradient may also be suggestive of IPAH and CTEPH.38 Desaturation during exercise occurs in all forms of PAH because of the inability of the failing right ventricle to increase cardiac output adequately.1 Nocturnal oxygen desaturation, even in the absence of sleep-disordered breathing, is surprisingly common in PAH, occurring in up to 75% of IPAH patients.42Exquisite experimental work using MRI evaluation of right ventricular dysfunction in PAH has begun to appear in the literature,4344 with some authors proposing it may be superior to echocardiography in estimating pulmonary arterial pressure.44 In CTEPH, one report suggested that good correlation to V/Q results can be expected with MRI in experienced hands.4546 Noninvasive measures of right ventricular chamber size,20 shape, thickness, and mass can also be offered by MRI,47 and mean pulmonary arterial pressure has been shown to correlate with MRI measurement of right ventricular thickness, main pulmonary artery diameter,48 and right ventricular mass.49 Nonetheless, the incremental clinical value of MRI and computed tomographic techniques to traditional echocardiographic assessments in PAH have not been reported.1Measures of exercise intolerance may be helpful in diagnosing early PAH (before it is present at rest) as well as in predicting survival and response to therapy.5051 Because PAH patients are limited in the extent to which they are able to raise cardiac output in response to tissue oxygen demands, small increases in workload can result in significant hypoxemia. Reductions in maximum peak oxygen consumption (VO2 max), anaerobic threshold, peak O2 pulse, rate of increase in VO2, and ventilatory efficiency as assessed by cycle ergometry cardiopulmonary exercise testing correlate well with New York Heart Association functional class.52 In addition end-tidal partial pressure of carbon monoxide (PETCO2) in IPAH patients is significantly reduced at rest and exercise in proportion to physiologic disease severity, and this finding on cardiopulmonary exercise testing when accompanied by arterial hypoxemia should trigger consideration of pulmonary vasculopathy.53 Cardiopulmonary exercise testing has been found reproducible and safe without complications or fatalities in even the most severely exercise-intolerant PAH patient.54 Peak VO2 and peak systolic blood pressure during cardiopulmonary exercise testing have also been shown to independently predict survival in PAH patients.55 Peak VO2 measures and ventilatory efficiency by cardiopulmonary exercise testing also show progressive improvement in response to surgical thromboendarterectomy in CTEPH.56A simple and practical substitute for full cardiopulmonary exercise testing is the 6-minute walk test. This validated test shows strong correlation between the distance ambulated and peak VO2 seen on cardiopulmonary exercise testing,57 as well as to total pulmonary vascular resistance, mean right atrial pressure, baseline cardiac output, and New York Heart Association functional class.58 The 6-minute walk test can also predict disease progression and patient's response to therapy59 and is commonly used for this purpose clinically.While right-heart catheterization is ultimately required, a constellation of noninvasive tests exist to aid the clinician in consolidating his or her diagnosis of PAH. These include the electrocardiography, chest radiography, pulmonary function tests, nocturnal oximetry, blood serologies, computed tomography, Doppler echocardiography with and without “bubble” contrast, and cardiopulmonary exercise testing. While none of these taken in isolation are adequate to definitively establish the diagnosis, when assessed in combination these tests are most helpful in defining who should proceed to right-heart catheterization. All patients with unexplained PAH should undergo V/Q scanning to avoid missing surgically remediable CTEPH. While magnetic resonance imaging and contrast-enhanced computed tomographic angiography can be complimentary, pulmonary angiography remains the procedure of choice to define operability when CTEPH is uncovered.
No takes yet. Share an insight, caveat, or question.
Terence K. Trow (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: